<DOC>
	<DOCNO>NCT00006473</DOCNO>
	<brief_summary>Phase II trial study effectiveness oxaliplatin treat patient relapsed refractory non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate oxaliplatin patient relapse refractory non-Hodgkin 's lymphoma . II . Determine treatment-related toxicity drug patient . OUTLINE : This multicenter study . Patients stratify accord histologic subtype ( indolent vs aggressive ) . Patients receive oxaliplatin IV 2 hour day 1 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A maximum 72 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm recurrent refractory nonHodgkin 's lymphoma ( NHL ) histologic subtype Indolent Follicular small cleave cell Follicular mix cell Small lymphocytic Mucosaassociated lymphoid tissue ( MALT ) Monocytoid Bcell Waldenstrom 's macroglobulinemia Aggressive Follicular large cell Diffuse large cell Immunoblastic Mantle cell Ki1+ NHL Peripheral Tcell Angiocentric angioimmunoblastic Transformed lymphoma Bidimensionally measurable disease No 3 prior treatment regimen follow : Primary radiotherapy 1 regimen Combined therapy radiotherapy chemotherapy 1 regimen Alternating therapy 1 regimen No know brain metastasis Performance status ECOG 02 Performance status Karnofsky 50100 % WBC count least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal Creatinine normal Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No neuropathy great grade 1 No history allergy platinum compound antiemetic No uncontrolled illness No active infection Not pregnant nursing Fertile patient must use effective contraception No concurrent colonystimulating factor first course therapy At least 4 week since prior chemotherapy At least 4 week since prior radiotherapy No concurrent investigational drug No concurrent antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>